MANY ORGANIZATIONS, ONE TEAM

The VARI–SU2C Epigenetics Dream Team offers industry collaborators all the benefits of working with multiple institutions with the ease of contracting with a single organization. The team is supported by VARI's expert staff, which ensures that collaborations run smoothly and efficiently.

DEDICATED PROJECT TEAM
VARI's staff works closely with VARI–SU2C Epigenetics Dream Team scientists, clinicians and industry collaborators throughout the entire project, from protocol development to implementation.

PURSUING FEEDBACK
The project team actively engages in collaborations with pharmaceutical companies and other affiliated organizations to optimize experimental design.

IMPLEMENTATION CLEARINGHOUSE
VARI's staff facilitates contracts and logistics with a single lead VARI–SU2C Epigenetics Dream Team organization and principal investigator, streamlining and accelerating development while reducing the time to launch for clinical trials, preclinical studies and basic science projects.

The VARI–SU2C Epigenetics Dream Team currently is seeking project proposals from industry representatives and would like to hear from you. To discuss potential proposals, please contact:

INQUIRIES
Andrea Poma, MPA, CLP
andrea.poma@vai.org
616.234.5523

VAN ANDEL RESEARCH INSTITUTE

Van Andel Institute (VAI) is an independent nonprofit biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational organization that supports the work of more than 360 scientists, educators and staff. Van Andel Research Institute (VARI), VAI's research division, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson's and other diseases and translating those findings into effective therapies. The Institute's scientists work in on-site laboratories and participate in collaborative partnerships that span the globe.

For more information about Van Andel Institute, visit www.vai.org.

STAND UP TO CANCER®

Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established by film and media leaders who utilize the industry's resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. SU2C was formally launched on May 27, 2008, and to date, there have been five biennial "roadblock" televised fundraising specials.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late co-founder Laura Ziskin executive produced both the Sept. 5, 2008, and Sept. 10, 2010, broadcasts. Sung Poblete, Ph.D., R.N., has served as SU2C's president since 2011.

The American Association for Cancer Research (AACR), the world's first and largest professional organization dedicated to advancing cancer research, is the official Scientific Partner of Stand Up To Cancer. AACR is responsible for administering the grants and providing scientific oversight in conjunction with the SU2C Scientific Advisory Committee (SAC).

For more information about Stand Up To Cancer, visit www.standup2cancer.org.

AACR
American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer and serves as Scientific Partner to Stand Up To Cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 101 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,300 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer.

For more information about the AACR, visit www.AACR.org.

333 Bostwick Ave. NE, Grand Rapids, MI 49503 | 616.234.5000 | www.vai.org



HARNESSING THE POWER OF COLLABORATION

VAN ANDEL RESEARCH INSTITUTE-STAND UP TO CANCER

EPIGENETICS DREAM TEAM

VAN ANDEL RESEARCH INSTITUTE

STAND UP TO CANCER®



SHIFTING THE PARADIGM

Finding the cancer therapies of tomorrow requires visionary thinking and innovative research today. The Van Andel Research Institute–Stand Up To Cancer (VARI–SU2C) Epigenetics Dream Team couples the epigenetics expertise of leading scientists and clinicians with the clinical trial capacity and proficiency of world-renowned medical organizations.

Since launching in 2008, Stand Up To Cancer has been part of more than 140 collaborations involving 67 pharmaceutical, biotech and diagnostic industry partners across its research portfolio. The VARI–SU2C Epigenetics Dream Team works to build on these successes and the foundation established by the original SU2C Epigenetics Dream Team, which ran from 2009 to 2014, by moving promising cancer therapies forward into clinical trials. In addition to internally derived proposals, the VARI–SU2C Epigenetics Dream Team actively works with industry collaborators to develop novel epigenetic cancer therapies and biomarkers, and to usher them through the development process from basic science and preclinical work to clinical trials and correlative studies.

Once identified, team members champion the development of formal research proposals, which are selected through rigorous evaluation, including detailed protocol and financial analyses. Chosen projects undergo strict, objective scientific review by the American Association for Cancer Research (AACR) and oversight by the SU2C Scientific Advisory Committee, which provides additional confidence in the team's methods and results.

Epigenetic therapies are an exciting frontier in the battle against cancer. Through unprecedented collaboration, a commitment to exceptional and rigorous science, and support from its industry collaborators, the VARI–SU2C Epigenetics Dream Team strives to improve the standard of care for cancer patients.

MEET THE VARI-SU2C EPIGENETICS DREAM TEAM

Leadership

Peter Jones, Ph.D., D.Sc.
Co-leader

Chief Scientific Officer
Van Andel Research Institute



Stephen Baylin, M.D.
Co-leader

Professor, Van Andel Research Institute; Virginia and D.K. Ludwig Professor for Cancer Research and Co-head, Cancer Biology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Dream Team members

Anthony El-Khoueiry, M.D.
Medical Director, Clinical Investigations Support Office
Associate Professor of Clinical Medicine
University of Southern California Norris Comprehensive Cancer Center

Kirsten Grønbæk, M.D., DMSc.
Chief Physician and Professor
University of Copenhagen/Rigshospitalet

Patricia Kropf, M.D.
Deputy Director, Bone Marrow Transplant Program
Fox Chase Cancer Center

Jean-Pierre Issa, M.D.
Co-leader, Cancer Epigenetics
Director, Fels Institute for Cancer Research and Molecular Biology
Temple University and Fox Chase Cancer Center

Feyruz Rassool, Ph.D.
Associate Professor
University of Maryland School of Medicine

Charles Rudin, M.D., Ph.D.
Chief, Thoracic Oncology Service
Co-director, Druckenmiller Center for Lung Cancer Research
Memorial Sloan Kettering Cancer Center

A COLLABORATIVE APPROACH

The VARI–SU2C Epigenetics Dream Team provides industry collaborators with access to a broad range of expertise, leading-edge technologies and the infrastructure to enhance value and validate results.

BASIC EPIGENETICS RESEARCH
The VARI–SU2C Epigenetics Dream Team comprises thought leaders in epigenetics and cancer biology, with expertise in a range of areas including DNA repair, chromatin remodeling, DNA methylation and histone modifications.

CLINICAL TRIALS EXPERTISE
VARI–SU2C Epigenetics Dream Team clinical trials are designed and conducted by leading trialists from internationally recognized research centers and hospitals.

BEYOND THE TRIALS
Given the importance of molecular signatures, the VARI–SU2C Epigenetics Dream Team emphasizes conducting correlative studies and biobanking for future work.

WORK WITH THE TEAM

The VARI–SU2C Epigenetics Dream Team has broad interest in developing novel epigenetic therapies and biomarkers. Team members actively seek industry collaborators in five focus areas:

- Identification of combination therapies involving epigenetic mechanisms (TET2, PD-1, PDL-1, EZH2, HDAC), next generation DMNTis and combinations with immune checkpoint inhibitors
- Uniform correlative analysis of control and longitudinal treatment samples (both in solid tumors and hematological malignancies)
- Identification and development of target engagement biomarkers for epigenetic therapies
- Optimizing treatment schedules to maximize the impact of epigenetic priming and immune response to single and combination therapies
- Development of "basket" trials for multiple oncologic indications with defined subtypes/ subsets of molecular signatures thought to be predictive of outcomes